Ask Warren

S.Biomedics

304360 · KOSDAQ · ₩304360 · 에스바이오메딕스

₩19,190▼ ₩410 (2.09%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩4.8B₩4.4B₩4B₩3.2B₩4.8B₩4.5B₩4.4B₩3.4B
Cost of sales₩2.5B₩2B₩2.2B₩1.6B₩2.9B₩2.2B₩2.5B₩1.6B
Gross profit₩2.3B₩2.4B₩1.8B₩1.6B₩1.9B₩2.2B₩1.9B₩1.8B
Operating income−₩3.7B−₩3B−₩2.7B−₩1.9B−₩2B−₩1.7B−₩1.1B−₩1.3B
Net income₩2.8B−₩1.8B−₩7.9B₩146M₩2.5B−₩1.8B−₩1.5B₩1.4B
Net income to shareholders−₩6.8B−₩2.4B−₩501M−₩2.3B−₩3B−₩2.3B−₩1.5B₩1.6B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩76B₩37B₩41B₩40B₩42B₩44B₩45B₩35B
Current assets₩55B₩16B₩20B₩23B₩25B₩29B₩29B₩19B
Cash and equivalents₩40B₩4.9B₩6.1B₩6.2B₩4.7B₩6.6B₩4.5B₩8.9B
Total liabilities₩36B₩21B₩24B₩27B₩27B₩27B₩26B₩19B
Current liabilities₩8.4B₩8.5B₩12B₩4.8B₩12B₩12B₩12B₩6.9B
Borrowings₩22B₩5.9B₩13B₩19B₩18B₩18B₩18B₩10B
Total equity₩40B₩17B₩17B₩13B₩15B₩17B₩18B₩16B
Shareholders' equity₩30B₩8.2B₩8.7B₩5.8B₩7.6B₩10B₩12B₩10B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩2.1B−₩3.4B₩1.9B−₩3.5B−₩2.2B−₩158M−₩487M−₩1.1B
Capital spending₩1.3B₩180M₩3.9B−₩1.5B₩1.9B₩112M₩824M₩206M
Free cash flow−₩3.3B−₩3.6B−₩1.9B−₩5B−₩4.1B−₩270M−₩1.3B−₩1.3B

Consolidated where available. Amounts in won.

Also known as: S.Biomedics / 에스바이오메딕스 / 304360 / KRX:304360

Source: KRX statistical information